Although we found that IRF1 and IRF5 were similarly expressed in normal breast tissue and patients with ADH or IDC, significant differences were observed in DCIS suggesting the unique utilization of these two biomarkers for diagnosis and prognosis. This evidence concerns the gene IRF5 and ductal breast carcinoma in situ.